302. レーベル遺伝性視神経症 Disease details / Clinical trials / Drug dev / DR info

Béfizal
   Hôpital Necker-Enfants Malades
      2019   Phase 2/Phase 3   NCT04561466   France
Cyclosporine
   University Hospital, Angers
      2011   Phase 2   NCT02176733   France
Glycerol tributyrate
   George Washington University
      2025   Phase 1/Phase 2   NCT06792500   United States
GS010
   GENSIGHT BIOLOGICS
      2019   Phase 3   EUCTR2017-002187-40-NL   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-IT   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-GB   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-FR   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-ES   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-BE   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 4   EUCTR2017-002153-11-IT   France;Germany;Italy;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002153-11-GB   France;Germany;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001266-26-IT   France;Germany;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001265-11-IT   France;Germany;Italy;United Kingdom;United States
   GENSIGHT-BIOLOGICS
      2016   Phase 3   EUCTR2015-001266-26-DE   France;Germany;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001265-11-DE   France;Germany;Italy;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001266-26-GB   France;Germany;Italy;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001265-11-GB   France;Germany;Italy;United Kingdom;United States
      2013   Phase 1;Phase 2   EUCTR2013-001405-90-FR   France
   GenSight Biologics
      2019   -   NCT03672968   -
      2014   Phase 1/Phase 2   NCT02064569   France
Idebenone
   Beijing Tongren Hospital, CMU
      2018   -   ChiCTR-IPR-17013821   China
   Hyogo College of Medicine
      2013   Phase 1,2   JPRN-UMIN000017939   Japan
   SANTHERA PHARMACEUTICALS
      -   Phase 4   EUCTR2015-004405-16-IT   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom
   Santhera Pharmaceuticals
      2016   Phase 4   NCT02774005   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      2016   -   NCT02771379   Austria;France;Germany;Greece;Italy;Netherlands
   Santhera Pharmaceuticals (Switzerland) Limited
      2017   Phase 4   EUCTR2015-004405-16-BG   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-004405-16-PT   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-004405-16-ES   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain
      2016   Phase 4   EUCTR2015-004405-16-DE   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-004405-16-BE   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-004405-16-AT   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      -   Phase 4   EUCTR2015-004405-16-PL   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
IEM-EP
   Region Stockholm
      2008   -   NCT06376279   -
Injection needle
   Neurophth Therapeutics Inc
      2023   Phase 1/Phase 2   NCT05293626   United States
KH176
   Khondrion BV
      2015   Phase 1   NCT02544217   Belgium
Lenadogene nolparvovec
   GENSIGHT BIOLOGICS
      2019   Phase 3   EUCTR2017-002187-40-NL   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-IT   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-GB   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-FR   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-ES   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-BE   Belgium;France;Italy;Netherlands;Spain;United Kingdom
Mecobalamin
   Beijing Tongren Hospital, CMU
      2018   -   ChiCTR-IPR-17013821   China
Nadh
   GENSIGHT BIOLOGICS
      2019   Phase 3   EUCTR2017-002187-40-NL   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-GB   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-FR   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-ES   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-BE   Belgium;France;Italy;Netherlands;Spain;United Kingdom
NFS-02 injection
   Neurophth Therapeutics Inc
      2023   Phase 1/Phase 2   NCT05820152   China;United States
NR082 injection
   Neurophth Therapeutics Inc
      2023   Phase 1/Phase 2   NCT05293626   United States
   Wuhan Neurophth Biotechnology Limited Company
      2021   Phase 2/Phase 3   NCT04912843   China
Pending
   GENSIGHT BIOLOGICS
      2016   Phase 3   EUCTR2015-001265-11-IT   France;Germany;Italy;United Kingdom;United States
   GENSIGHT-BIOLOGICS
      2016   Phase 3   EUCTR2015-001266-26-DE   France;Germany;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001265-11-DE   France;Germany;Italy;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001266-26-GB   France;Germany;Italy;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001265-11-GB   France;Germany;Italy;United Kingdom;United States
RAAV2-ND1
   Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China
      2021   Phase 0   ChiCTR2000041574   China
RAAV2-ND4
   Bin Li
      2018   -   NCT03428178   China
      2011   -   NCT01267422   China
   Huazhong University of Science and Technology
      2017   Phase 2/Phase 3   NCT03153293   China
RAAV2/2-ND4 vector
   GENSIGHT BIOLOGICS
      2016   Phase 3   EUCTR2015-001266-26-IT   France;Germany;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001265-11-IT   France;Germany;Italy;United Kingdom;United States
   GENSIGHT-BIOLOGICS
      2016   Phase 3   EUCTR2015-001266-26-DE   France;Germany;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001265-11-DE   France;Germany;Italy;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001266-26-GB   France;Germany;Italy;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001265-11-GB   France;Germany;Italy;United Kingdom;United States
      2013   Phase 1;Phase 2   EUCTR2013-001405-90-FR   France
Raxone
   SANTHERA PHARMACEUTICALS
      -   Phase 4   EUCTR2015-004405-16-IT   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom
   Santhera Pharmaceuticals (Switzerland) Limited
      2017   Phase 4   EUCTR2015-004405-16-BG   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-004405-16-PT   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-004405-16-ES   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain
      2016   Phase 4   EUCTR2015-004405-16-DE   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-004405-16-BE   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-004405-16-AT   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
      -   Phase 4   EUCTR2015-004405-16-PL   Austria;Belgium;Bulgaria;Germany;Italy;Poland;Portugal;Spain;United Kingdom;United States
Recombinant AAV vector serotype 2 containing THE human wild type mitochondrial ND4 gene
   GENSIGHT BIOLOGICS
      2019   Phase 3   EUCTR2017-002187-40-NL   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-GB   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-FR   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-ES   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-002187-40-BE   Belgium;France;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 4   EUCTR2017-002153-11-IT   France;Germany;Italy;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002153-11-GB   France;Germany;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001266-26-IT   France;Germany;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001265-11-IT   France;Germany;Italy;United Kingdom;United States
   GENSIGHT-BIOLOGICS
      2016   Phase 3   EUCTR2015-001266-26-DE   France;Germany;Italy;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001265-11-DE   France;Germany;Italy;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001266-26-GB   France;Germany;Italy;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001265-11-GB   France;Germany;Italy;United Kingdom;United States
      2013   Phase 1;Phase 2   EUCTR2013-001405-90-FR   France
Recombinant AAV vector serotype 2 containing THE human wild typemitochondrial ND4 gene
   GENSIGHT BIOLOGICS
      2018   Phase 3   EUCTR2017-002187-40-IT   Belgium;France;Italy;Netherlands;Spain;United Kingdom
Sham injection
   Wuhan Neurophth Biotechnology Limited Company
      2021   Phase 2/Phase 3   NCT04912843   China
Vitamin B1
   Beijing Tongren Hospital, CMU
      2018   -   ChiCTR-IPR-17013821   China